Abbvie Inc
NYSE:ABBV
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
US |
Abbvie Inc
NYSE:ABBV
|
295.7B USD | 9.3 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
143.7B USD | 9.9 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.5B USD | 10.6 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.6B USD | 6.7 | ||
AU |
CSL Ltd
ASX:CSL
|
134.5B AUD | 13.3 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.5B USD | 4.5 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 24.2 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
40.6B USD | 15.1 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
28.9B USD | 4.7 | ||
KR |
Celltrion Inc
KRX:068270
|
36.8T KRW | 35.9 | ||
IE |
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 9.7 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.